Complete Filing Data
Definium Therapeutics, Inc. reported Stockholders Equity of $332.33 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Definium Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income * | -$183.8M | -$108.7M | -$95.7M | -$56.8M | -$93.0M | -$33.9M | |
| Comprehensive Income Net Of Tax | -$183.5M | -$108.2M | -$96.0M | -$57.2M | -$92.3M | -$33.7M | |
| Research And Development Expense | $117.7M | $65.3M | $52.1M | $36.2M | $34.8M | $18.6M | |
| Other Nonoperating Income Expense | -$17.5M | -$4.8M | -$1.9M | $9.5M | -$339.0K | -$907.0K | |
| Operating Income Loss | -$166.3M | -$103.9M | -$93.9M | -$66.3M | -$93.9M | -$33.0M | |
| Operating Expenses | $166.3M | $103.9M | $93.9M | $66.3M | $93.9M | $33.0M | |
| General And Administrative Expense | $48.6M | $38.6M | $41.7M | $30.2M | $59.1M | $14.4M | |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$64.0K | $476.0K | -$284.0K | -$419.0K | $762.0K | $284.0K | |
| Amortization Of Intangible Assets | $0.00 | $527.0K | $3.2M | $3.2M | $2.6M | $0.00 | |
| Interest Income Expense Net | $4.7M | $1.5M | -$359.0K | -$164.0K | |||
| Interest Expense | $5.5M | $2.3M | $920.0K | ||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$56.8M | -$94.2M | -$33.9M | -$10.7M | |||
| Income Tax Expense Benefit | -$1.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$67.3M | -$42.7M | -$23.3M | -$13.7M | -$5.9M | -$54.4M | -$17.9M | -$29.1M | -$24.8M | -$16.5M | -$17.0M | -$18.5M | -$17.2M | -$45.3M | -$13.8M |
| Comprehensive Income Net Of Tax | -$67.1M | -$42.7M | -$23.4M | -$13.7M | -$5.9M | -$53.9M | -$17.5M | -$29.4M | -$24.8M | -$16.6M | -$17.1M | -$18.5M | -$17.6M | -$44.5M | -$13.7M |
| Research And Development Expense | $31.0M | $29.8M | $23.4M | $17.2M | $14.6M | $11.7M | $13.2M | $14.8M | $12.6M | $7.8M | $9.3M | $10.2M | $9.0M | $8.1M | $6.8M |
| Other Nonoperating Income Expense | -$21.6M | -$1.8M | $8.8M | $11.1M | $18.6M | -$32.2M | $3.7M | $54.0K | -$4.0M | $498.0K | -$14.0K | $54.0K | $31.0K | -$32.0K | $89.0K |
| Operating Income Loss | -$45.7M | -$40.9M | -$32.2M | -$24.8M | -$24.5M | -$22.2M | -$21.6M | -$29.2M | -$20.9M | -$17.0M | -$16.9M | -$18.5M | -$17.2M | -$45.2M | -$13.8M |
| Operating Expenses | $45.7M | $40.9M | $32.2M | $24.8M | $24.5M | $22.2M | $21.6M | $29.2M | $20.9M | $17.0M | $16.9M | $18.5M | $17.2M | $45.2M | $13.8M |
| General And Administrative Expense | $14.7M | $11.1M | $8.8M | $7.6M | $9.8M | $10.5M | $8.4M | $14.4M | $8.3M | $9.2M | $7.6M | $8.3M | $8.2M | $37.1M | $7.0M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$2.0K | -$31.0K | -$27.0K | -$12.0K | -$3.0K | $493.0K | $415.0K | -$279.0K | $14.0K | -$107.0K | -$147.0K | -$49.0K | -$383.0K | $704.0K | $59.0K |
| Amortization Of Intangible Assets | $0.00 | $0.00 | $0.00 | $527.0K | $800.0K | $800.0K | $791.0K | $800.0K | $800.0K | $780.0K | $800.0K | $800.0K | $260.0K | ||
| Interest Income Expense Net | $1.2M | $1.3M | $1.3M | $360.0K | $82.0K | -$27.0K | -$64.0K | -$69.0K | -$87.0K | ||||||
| Interest Expense | $1.3M | $2.3M | $602.0K | $727.0K | $466.0K | $434.0K | $328.0K | $77.0K | $76.0K | ||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$16.5M | -$17.0M | -$17.2M | -$45.3M | |||||||||||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $332.3M | $241.4M | $78.1M | $150.9M | $151.7M | $75.9M | $4.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $257.8M | $273.7M | $99.7M | $142.1M | $133.5M | $80.1M | $6.7M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$15.9M | $174.0M | -$42.4M | $8.6M | $53.4M | $73.4M | |
| Retained Earnings Accumulated Deficit | -$582.7M | -$398.9M | -$290.2M | -$194.5M | -$137.7M | -$44.6M | |
| Prepaid Expense And Other Assets Current | $7.7M | $7.9M | $4.2M | $3.9M | $3.7M | $1.4M | |
| Liabilities Current | $66.7M | $38.8M | $32.2M | $17.9M | $10.4M | $3.0M | |
| Liabilities And Stockholders Equity | $440.1M | $302.2M | $124.5M | $170.0M | $164.0M | $81.5M | |
| Liabilities | $107.8M | $60.7M | $46.4M | $19.1M | $12.3M | $5.7M | |
| Goodwill | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $0.00 | |
| Cash And Cash Equivalents At Carrying Value | $257.8M | $273.7M | $99.7M | $142.1M | $133.5M | $80.1M | |
| Assets Current | $419.3M | $281.6M | $103.9M | $146.1M | $137.2M | $81.5M | |
| Assets | $440.1M | $302.2M | $124.5M | $170.0M | $164.0M | $81.5M | |
| Additional Paid In Capital Common Stock | $913.9M | $639.5M | $368.0M | $344.8M | $288.3M | $120.2M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $1.1M | $819.0K | $343.0K | $627.0K | $1.0M | $284.0K | |
| Accrued Liabilities Current | $20.4M | $12.8M | $11.6M | $5.9M | $6.2M | $986.0K | |
| Accounts Payable Current | $5.3M | $2.0M | $4.1M | $2.1M | $4.2M | $2.0M | |
| Financing Warrants Liability | $40.9M | $24.0M | $16.5M | $9.9M | |||
| Other Assets Noncurrent | $862.0K | $613.0K | $224.0K | $331.0K | |||
| Other Liabilities Long Term | $40.0K | $32.0K | $1.2M | $870.0K | |||
| Other Liabilities Noncurrent | $496.0K | $32.0K | $1.2M | $1.9M | |||
| Indefinite Lived Intangible Assets Excluding Goodwill | $527.0K | $3.7M | $6.9M | ||||
| Other Non Cash Adjustments | $230.0K | $787.0K | $56.0K | $43.0K | |||
| Gains Losses On Extinguishment Of Debt | $0.00 | $2.5M | $0.00 | ||||
| Payment Of Deferred Financing Fees Related To At The Market | $0.00 | $499.0K | $0.00 | ||||
| Reclass Of Deferred Financing Fees To Additional Paid In Capital | $0.00 | $332.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $130.6M | $185.4M | $222.8M | $262.2M | $202.0M | $196.1M | $96.0M | $106.0M | $130.3M | $153.6M | $124.5M | $136.8M | $164.3M | $171.6M | $180.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $20.0M | $33.4M | $82.9M | $295.3M | $243.1M | $252.3M | $117.7M | $116.9M | $129.4M | $154.5M | $105.7M | $120.5M | $145.9M | $157.1M | $160.0M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$190.9M | $152.6M | -$12.7M | -$13.1M | $79.9M | ||||||||||
| Retained Earnings Accumulated Deficit | -$532.2M | -$465.0M | -$422.2M | -$364.1M | -$350.5M | -$344.6M | -$266.3M | -$248.4M | -$219.3M | -$189.6M | -$173.1M | -$156.1M | |||
| Prepaid Expense And Other Assets Current | $6.8M | $6.1M | $9.3M | $4.1M | $4.6M | $3.1M | $2.4M | $2.9M | $3.0M | $1.8M | $3.2M | $2.8M | |||
| Liabilities Current | $65.4M | $38.0M | $30.5M | $33.3M | $41.8M | $65.3M | $31.2M | $35.1M | $24.1M | $26.0M | $7.9M | $10.6M | |||
| Liabilities And Stockholders Equity | $236.9M | $265.1M | $275.3M | $319.8M | $268.1M | $275.5M | $141.6M | $142.1M | $155.5M | $180.9M | $134.3M | $149.2M | |||
| Liabilities | $106.3M | $79.7M | $52.5M | $57.6M | $66.1M | $79.5M | $45.6M | $36.1M | $25.2M | $27.3M | $9.8M | $12.4M | |||
| Goodwill | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | |||
| Cash And Cash Equivalents At Carrying Value | $20.0M | $33.4M | $82.9M | $295.3M | $243.1M | $252.3M | $117.7M | $116.9M | $129.4M | $154.5M | $105.7M | $120.5M | |||
| Assets Current | $215.8M | $189.1M | $221.7M | $299.4M | $247.7M | $255.5M | $120.1M | $119.8M | $132.4M | $156.5M | $109.1M | $123.2M | |||
| Assets | $236.9M | $265.1M | $275.3M | $319.8M | $268.1M | $275.5M | $141.6M | $142.1M | $155.5M | $180.9M | $134.3M | $149.2M | |||
| Additional Paid In Capital Common Stock | $661.8M | $649.6M | $644.2M | $625.5M | $551.7M | $539.8M | $361.5M | $354.0M | $349.0M | $342.4M | $296.7M | $291.9M | |||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $1.0M | $807.0K | $802.0K | $821.0K | $833.0K | $836.0K | $777.0K | $362.0K | $641.0K | $743.0K | $850.0K | $997.0K | |||
| Accrued Liabilities Current | $19.0M | $14.8M | $11.5M | $8.8M | $8.2M | $10.0M | $10.0M | $10.0M | $6.7M | $7.5M | $7.1M | $7.2M | |||
| Accounts Payable Current | $8.1M | $4.2M | $2.3M | $2.1M | $2.9M | $7.6M | $7.7M | $8.6M | $2.3M | $824.0K | $732.0K | $3.3M | |||
| Financing Warrants Liability | $38.3M | $18.9M | $16.7M | $22.3M | $30.7M | $47.7M | $13.5M | $16.6M | $15.1M | $17.7M | |||||
| Other Assets Noncurrent | $1.2M | $1.2M | $606.0K | $493.0K | $534.0K | $144.0K | $229.0K | $268.0K | $300.0K | ||||||
| Other Liabilities Long Term | $0.00 | $17.0K | $95.0K | $60.0K | |||||||||||
| Other Liabilities Noncurrent | $519.0K | $543.0K | $15.0K | $349.0K | $992.0K | $1.1M | $1.3M | $1.9M | |||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | $1.3M | $2.1M | $2.9M | $4.5M | $5.3M | $6.1M | |||||||||
| Other Non Cash Adjustments | -$19.0K | $75.0K | $14.0K | ||||||||||||
| Gains Losses On Extinguishment Of Debt | $2.5M | ||||||||||||||
| Payment Of Deferred Financing Fees Related To At The Market | |||||||||||||||
| Reclass Of Deferred Financing Fees To Additional Paid In Capital | $0.00 | $332.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Allocated Share Based Compensation Expense | $20.1M | $16.9M | $15.2M | $13.7M | $42.7M | $7.4M |
| Net Cash Provided By Used In Operating Activities | -$131.6M | -$79.1M | -$64.4M | -$50.1M | -$45.8M | -$23.6M |
| Net Cash Provided By Used In Financing Activities | $267.3M | $253.2M | $21.8M | $59.1M | $98.8M | $96.7M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$152.0K | $4.3M | -$39.0K | $260.0K | $2.2M | $1.4M |
| Increase Decrease In Accrued Liabilities | $6.0M | $3.1M | $5.3M | -$416.0K | $4.6M | -$242.0K |
| Increase Decrease In Accounts Payable | $3.3M | -$2.1M | $2.0M | -$2.1M | $1.3M | $544.0K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -$7.0K | -$30.0K | $79.0K | -$309.0K | $742.0K | $284.0K |
| Proceeds From Warrant Exercises | $3.8M | $8.3M | $114.0K | $708.0K | $11.2M | $24.5M |
| Proceeds From Stock Options Exercised | $625.0K | $716.0K | $49.0K | $206.0K | $5.7M | $648.0K |
| Proceeds From Issuance Of Common Stock | $0.00 | $984.0K | $7.5M | $42.3M | $81.9M | $72.0M |
| Payments Related To Tax Withholding For Share Based Compensation | $0.00 | $54.0K | $0.00 | $407.0K | ||
| Increase Decrease In Other Noncurrent Assets | -$30.0K | -$48.0K | -$51.0K | $180.0K | ||
| Payments Of Financing Costs | $447.0K | $128.0K | $844.0K | |||
| Payments Of Stock Issuance Costs | $15.9M | $16.1M | $0.00 | $395.0K | ||
| Proceeds From Long Term Lines Of Credit | $42.0M | $10.0M | $15.0M | |||
| Net Cash Provided By Used In Investing Activities | -$151.6M | $0.00 | -$297.0K | |||
| Increase Decrease In Contribution Payable | -$870.0K | -$713.0K | $2.6M | |||
| Stock Issued During Period Value Share Based Compensation | $190.0K | $249.0K | ||||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans | 412.0K | 0.00 | ||||
| Proceeds From At The Market Offering Program Net Of Issuance Costs |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allocated Share Based Compensation Expense | $5.8M | $5.3M | $3.4M | $3.8M | $5.4M | $3.7M | $4.2M | $3.8M | $3.8M | $4.3M | $4.3M | $3.8M | $4.1M | $33.0M | $1.3M |
| Net Cash Provided By Used In Operating Activities | -$29.4M | -$16.6M | -$13.3M | -$12.9M | -$10.0M | ||||||||||
| Net Cash Provided By Used In Financing Activities | $1.0M | $169.2M | $583.0K | -$166.0K | $90.0M | ||||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $1.4M | -$468.0K | -$909.0K | -$922.0K | $732.0K | ||||||||||
| Increase Decrease In Accrued Liabilities | -$1.3M | -$2.7M | $703.0K | $994.0K | $1.4M | ||||||||||
| Increase Decrease In Accounts Payable | $258.0K | $1.5M | $209.0K | -$843.0K | $1.6M | ||||||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -$12.0K | -$21.0K | $15.0K | -$35.0K | $313.0K | ||||||||||
| Proceeds From Warrant Exercises | $579.0K | $1.7M | $118.0K | $6.7M | |||||||||||
| Proceeds From Stock Options Exercised | $237.0K | $465.0K | $123.0K | $1.2M | |||||||||||
| Proceeds From Issuance Of Common Stock | $583.0K | $82.1M | |||||||||||||
| Payments Related To Tax Withholding For Share Based Compensation | $0.00 | $54.0K | $407.0K | ||||||||||||
| Increase Decrease In Other Noncurrent Assets | $10.0K | -$66.0K | -$18.0K | ||||||||||||
| Payments Of Financing Costs | $0.00 | $128.0K | |||||||||||||
| Payments Of Stock Issuance Costs | $0.00 | $8.7M | |||||||||||||
| Proceeds From Long Term Lines Of Credit | |||||||||||||||
| Net Cash Provided By Used In Investing Activities | -$162.5M | $0.00 | -$316.0K | ||||||||||||
| Increase Decrease In Contribution Payable | -$60.0K | -$44.0K | |||||||||||||
| Stock Issued During Period Value Share Based Compensation | $57.0K | $68.0K | $66.0K | ||||||||||||
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans | 186.0K | 0.00 | |||||||||||||
| Proceeds From At The Market Offering Program Net Of Issuance Costs | $0.00 | $984.0K | $583.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$2.06 | -$1.54 | -$2.44 | -$1.84 | -$3.40 | -$0.13 |
| Weighted Average Number Of Shares Outstanding Basic | 89.3M | 70.5M | 39.2M | 30.9M | 27.4M | |
| Weighted Average Number Of Diluted Shares Outstanding | 89.3M | 70.5M | 39.2M | 30.9M | 27.4M | |
| Earnings Per Share Basic | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | |
| Common Stock Shares Outstanding | 98.8M | 75.1M | 41.1M | 38.0M | 28.1M | |
| Common Stock Shares Issued | 98.8M | 75.1M | 41.1M | 38.0M | 28.1M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.78 | -$0.50 | -$0.35 | -$0.27 | -$0.26 | -$1.14 | -$0.45 | -$0.76 | -$0.65 | -$0.56 | -$0.60 | -$0.66 | -$0.61 | -$0.11 | -$0.04 |
| Weighted Average Number Of Shares Outstanding Basic | 85.9M | 85.3M | 85.1M | 77.9M | 71.9M | 47.9M | 39.7M | 38.6M | 38.1M | 29.3M | 28.2M | 28.1M | 28.0M | 410.8M | |
| Weighted Average Number Of Diluted Shares Outstanding | 85.9M | 85.3M | 87.1M | 80.2M | 75.3M | 47.9M | 39.7M | 38.6M | 38.1M | 29.3M | 28.2M | 28.1M | 28.0M | 410.8M | |
| Earnings Per Share Basic | $-0.78 | $-0.50 | $-0.27 | $-0.18 | $-0.08 | $-1.14 | $-0.45 | $-0.76 | $-0.65 | $-0.56 | $-0.60 | $-0.66 | $-0.61 | $-0.11 | |
| Common Stock Shares Outstanding | 76.8M | 75.8M | 75.5M | 81.6M | 72.1M | 71.2M | 40.1M | 38.8M | 38.3M | 37.5M | 426.7M | ||||
| Common Stock Shares Issued | 76.8M | 75.8M | 75.5M | 81.6M | 72.1M | 71.2M | 40.1M | 38.8M | 38.3M | 37.5M | 426.7M | ||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $20.1M | $16.9M | $15.2M | $13.7M | $37.0M | $1.6M |
| Foreign Currency Transaction Gain Loss Before Tax | -$131.0K | -$638.0K | $157.0K | $195.0K | -$86.0K | $130.0K |
| Stock Issued During Period Value Stock Options Exercised | $49.0K | $206.0K | $5.7M | $648.0K | ||
| Stock Issued During Period Value New Issues | $242.8M | $234.3M | $7.8M | $42.3M | $81.9M | $71.2M |
| Fair Value Adjustment Of Warrants | $22.8M | $15.9M | $6.6M | -$7.8M | ||
| Investment Income Interest And Dividend | $11.0M | $11.6M | $5.6M | |||
| Other Income | -$51.0K | $2.0K | $106.0K | |||
| Stock Issued During Period Value Warrants Exercised | $708.0K | $11.2M | $24.5M | |||
| Foreign Currency Transaction Gain Loss Unrealized | $0.00 | -$506.0K | $363.0K | $148.0K | ||
| Long Term Line Of Credit | $40.6M | $21.9M | $14.1M | |||
| Stock Issued1 | $5.9M | $8.4M | $64.0K | |||
| Interest Paid Net | $5.3M | $2.2M | $534.0K | |||
| Stock Issued During Period Shares Stock Options Exercised | 216.0K | 13.3K | 38.3K | 12.1M | ||
| Stock Issued During Period Value Upon Settlement Of Restricted Stock Unit Awards Net Of Shares Withheld For Tax | -54.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $5.8M | $5.3M | $3.4M | $3.8M | $5.4M | $3.7M | $4.2M | $3.8M | $3.6M | $4.3M | $4.2M | $3.8M | $4.5M | $27.6M | $1.2M |
| Foreign Currency Transaction Gain Loss Before Tax | -$39.0K | -$49.0K | -$19.0K | -$32.0K | -$32.0K | -$525.0K | -$439.0K | $247.0K | -$52.0K | $138.0K | -$89.0K | $45.0K | -$40.0K | -$35.0K | $8.0K |
| Stock Issued During Period Value Stock Options Exercised | $98.0K | $80.0K | $237.0K | $32.0K | $109.0K | $530.0K | $49.0K | $42.0K | $41.0K | $123.0K | $315.0K | $4.1M | $1.2M | ||
| Stock Issued During Period Value New Issues | $70.0M | $164.3M | $3.1M | $1.3M | $583.0K | $41.4M | -$4.0K | -$186.0K | $82.1M | ||||||
| Fair Value Adjustment Of Warrants | $22.5M | $2.2M | -$7.0M | -$8.4M | -$13.4M | $32.9M | -$3.0M | $1.5M | $5.2M | ||||||
| Investment Income Interest And Dividend | $2.3M | $2.8M | $2.4M | $3.5M | $3.1M | $1.7M | $1.5M | $1.4M | $1.4M | ||||||
| Other Income | -$51.0K | $0.00 | -$7.0K | $36.0K | $135.0K | $72.0K | $168.0K | ||||||||
| Stock Issued During Period Value Warrants Exercised | $178.0K | $590.0K | $118.0K | $509.0K | $4.0M | $6.7M | |||||||||
| Foreign Currency Transaction Gain Loss Unrealized | $0.00 | -$514.0K | |||||||||||||
| Long Term Line Of Credit | $40.4M | $41.2M | $22.0M | $24.3M | $24.3M | $14.2M | $14.1M | ||||||||
| Stock Issued1 | $295.0K | $1.7M | |||||||||||||
| Interest Paid Net | $602.0K | $434.0K | |||||||||||||
| Stock Issued During Period Shares Stock Options Exercised | 53.5K | 118.9K | 317.7K | ||||||||||||
| Stock Issued During Period Value Upon Settlement Of Restricted Stock Unit Awards Net Of Shares Withheld For Tax | -54.0K |
Most recent annual filing with the SEC: February 26, 2026
Data sourced from SEC EDGAR public filings as of August 4, 2026.